Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 56-69 , January 2004

Implications of PET based molecular imaging on the current and future practice of medicine

  • Abass Alavi

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    • Corresponding Author InformationAddress reprint requests to Abass Alavi, MD, Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, 110 Donner Bldg., 3400 Spruce St., Philadelphia, PA 19104, USA
    • ,
  • Justin W Kung

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    • ,
  • Hongming Zhuang

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

References 

  1. Schaner EG, Chang AE, Doppman JL, et al.  Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules (A prospective radiologic-pathologic study). AJR Am J Roentgenol. 1978;131:51–54
  2. Vanel D, Henry-Amar M, Lumbroso J, et al.  Pulmonary evaluation of patients with osteosarcoma (Roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy). AJR Am J Roentgenol. 1984;143:519–523
  3. Muhm JR, Brown LR, Crowe JK, et al.  Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules. AJR Am J Roentgenol. 1978;131:981–984
  4. Crim JR, Cracchiolo A, Bassett LW, et al.  Magnetic resonance imaging of the hindfoot. Foot & Ankle. 1989;10:1–7
  5. Hilpert PL, Friedman AC, Radecki PD, et al.  MRI of hemorrhagic renal cysts in polycystic kidney disease. AJR Am J Roentgenol. 1986;146:1167–1172
  6. Semelka RC, Bagley AS, Brown ED, et al.  Solitary hepatic metastasis (Comparison of dynamic contrast-enhanced CT and MR imaging with fat-suppressed T2-weighted, breath-hold T1-weighted FLASH, and dynamic gadolinium-enhanced FLASH sequences). J Magn Reson Imaging. 1994;4:319–323
  7. Stark DD, Wittenberg J, Butch RJ, et al.  Hepatic metastases (Randomized, controlled comparison of detection with MR imaging and CT). Radiology. 1987;165:399–406
  8. Czernin J, Phelps ME. Positron emission tomography scanning (Current and future applications). Annu Rev Med. 2002;53:89–112
  9. Calautti C, Baron JC. Functional neuroimaging studies of motor recovery after stroke in adults (a review). Stroke. 2003;34:1553–1566
  10. Grenier N, Basseau F, Ries M, et al.  Functional MRI of the kidney. Abdom Imaging. 2003;28:164–175
  11. Ntziachristos V, Chance B. Probing physiology and molecular function using optical imaging (Applications to breast cancer). Breast Cancer Res. 2001;3:41–46
  12. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light (new technological advances that enable in vivo molecular imaging). Eur Radiol. 2003;13:195–208
  13. Dearling JL, Lewis JS, Mullen GE, et al.  Design of hypoxia-targeting radiopharmaceuticals (selective uptake of copper-64 complexes in hypoxic cells in vitro). Eur J Nucl Med. 1998;25:788–792
  14. Alavi A, Reivich M. The conception of FDG-PET imaging. Semin Nucl Med. 2002;32:2–5 (editorial)
  15. Alavi A, Hirsch LJ. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography (Evolution over the past 2 decades). Semin Nucl Med. 1991;21:58–81
  16. Gambhir SS, Barrio JR, Herschman HR, et al.  Assays for noninvasive imaging of reporter gene expression. Nucl Med Biol. 1999;26:481–490
  17. Cherry SR. Fundamentals of positron emission tomography and applications in preclinical drug development. J Clin Pharmacol. 2001;41:482–491
  18. Vaalburg W, Hendrikse NH, de Vries EF. Drug development, radiolabelled drugs and PET. Ann Med. 1999;31:432–437
  19. Newberg A, Alavi A, Reivich M. Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med. 2002;32:13–34
  20. Engel J, Kuhl DE, Phelps ME, et al.  Local cerebral metabolism during partial seizures. Neurology. 1983;33:400–413
  21. Theodore WH, Newmark ME, Sato S, et al.  [18F]fluorodeoxyglucose positron emission tomography in refractory complex partial seizures. Ann Neurol. 1983;14:429–437
  22. Barrington SF, Koutroumanidis M, Agathonikou A, et al.  Clinical value of “ictal” FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia. 1998;39:753–766
  23. Moran NF, Lemieux L, Kitchen ND, et al.  Extrahippocampal temporal lobe atrophy in temporal lobe epilepsy and mesial temporal sclerosis. Brain. 2001;124:167–175
  24. Kobayashi E, D’Agostino MD, Lopes-Cendes I, et al.  Hippocampal atrophy and T2-weighted signal changes in familial mesial temporal lobe epilepsy. Neurology. 2003;60:405–409
  25. Meyer PT, Cortes-Blanco A, Pourdehnad M, et al.  Inter-modality comparisons of seizure focus lateralization in complex partial seizures. Eur J Nucl Med. 2001;28:1529–1540
  26. Imbimbo BP, Martelli P, Troetel WM, et al.  Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease. Neurology. 1999;52:700–708
  27. Morris JC, Cyrus PA, Orazem J, et al.  Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology. 1998;50:1222–1230
  28. Knapp MJ, Knopman DS, Solomon PR, et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. The Tacrine Study Group. JAMA. 1994;271:985–991
  29. Rogers SL, Farlow MR, Doody RS, et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology. 1998;50:136–145
  30. Rosler M, Anand R, Cicin-Sain A, et al.  Efficacy and safety of rivastigmine in patients with Alzheimer’s disease (International randomised controlled trial). BMJ. 1999;318:633–638 [erratum appears in BMJ 322:1456, 2001]
  31. Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the [18F]fluorodeoxyglucose method. Ann Neurol. 1984;15:419–424
  32. Ishii K. Clinical application of positron emission tomography for diagnosis of dementia. Ann Nucl Med. 2002;16:515–525
  33. Alavi A, Dann R, Chawluk J, et al.  Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med. 1986;16:2–34
  34. Salmon E, Sadzot B, Maquet P, et al.  Differential diagnosis of Alzheimer’s disease with PET. J Nucl Med. 1994;35:391–398
  35. Van Heertum RL, Tikofsky RS. Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med. 2003;33:77–85
  36. Alavi A, Clark C, Fazekas F. Cerebral ischemia and Alzheimer’s disease (Critical role of PET and implications for therapeutic intervention). J Nucl Med. 1998;39:1363–1365
  37. Alavi A, Newberg AB, Souder E, et al.  Quantitative analysis of PET and MRI data in normal aging and Alzheimer’s disease (Atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators). J Nucl Med. 1993;34:1681–1687
  38. Davis MR, Votaw JR, Bremner JD, et al.  Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med. 2003;44:855–861
  39. Vingerhoets FJ, Schulzer M, Ruth TJ, et al.  Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson’s disease. J Nucl Med. 1996;37:421–426
  40. Huang WS, Chiang YH, Lin JC, et al.  Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson’s disease patients. J Nucl Med. 2003;44:999–1005
  41. Alavi A, Newberg AB. AMetabolic consequences of acute brain trauma (is there a role for PET?). J Nucl Med. 1996;37:1170–1172
  42. Newberg AB, Alavi A. Neuroimaging in patients with head injury. Semin Nucl Med. 2003;33:136–147
  43. Newberg A, Cotter A, Udeshi M, et al.  A metabolic imaging severity rating scale for the assessment of cognitive impairment. Clin Nucl Med. 2003;28:565–570
  44. Silverman DH, Small GW, Chang CY, et al.  Positron emission tomography in evaluation of dementia (Regional brain metabolism and long-term outcome). JAMA. 2001;286:2120–2127
  45. Mazziotta JC, Phelps ME, Pahl JJ, et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington’s disease. N Engl J Med. 1987;316:357–362
  46. Kuhl DE, Phelps ME, Markham CH, et al.  Cerebral metabolism and atrophy in Huntington’s disease determined by 18FDG and computed tomographic scan. Ann Neurol. 1982;12:425–434
  47. Kuwert T, Lange HW, Langen KJ, et al.  Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington’s disease. Psychiatry Res. 1989;29:361–362
  48. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32:35–46
  49. Wahl RL, Hawkins RA, Larson SM, et al.  Proceedings of a National Cancer Institute workshop (PET in oncology-A clinical research agenda). Radiology. 1994;193:604–606
  50. Rigo P, Paulus P, Kaschten BJ, et al.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641–1674
  51. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150–185
  52. Bury T, Dowlati A, Paulus P, et al.  Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med. 1996;23:204–206
  53. Albes JM, Lietzenmayer R, Schott U, et al.  Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thorac Cardiovasc Surg. 1999;47:42–47
  54. Coleman RE. PET in lung cancer. J Nucl Med. 1999;40:814–820
  55. Wahl RL. Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol. 2001;36:250–260
  56. Zhuang H, Sinha P, Pourdehnad M, et al.  The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun. 2000;21:793–798
  57. Bohuslavizki KH, Kluttman S, Sonnemann U, et al.  [F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region]. Laryngorhinootologie. 1999;78:445–449
  58. Bohuslavizki KH, Kluttman S, Kroger S, et al.  FDG PET detection of unknown primary tumors. J Nucl Med. 2000;41:816–822
  59. Braams JW, Pruim J, Kole AC, et al.  Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg. 1997;26:112–115
  60. Lassen U, Daugaard G, Eigtved A, et al.  18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer. 1999;35:1076–1082
  61. Kole AC, Nieweg OE, Pruim J, et al.  Detection of unknown occult primary tumors using positron emission tomography. Cancer. 1998;82:1160–1166
  62. Hustinx R, Smith RJ, Benard F, et al.  Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography (A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck). Eur J Nucl Med. 1999;26:1345–1348
  63. Keyes JW, Watson NE, Williams DW, et al.  FDG PET in head and neck cancer. AJR Am J Roentgenol. 1997;169:1663–1669
  64. Weihrauch MR, Re D, Bischoff S, et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol. 2002;81:20–25
  65. Delbeke D, Vitola JV, Sandler MP, et al.  Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196–1201
  66. Flamen P, Hoekstra OS, Homans F, et al.  Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer (The utility of positron emission tomography (PET)). Eur J Cancer. 2001;37:862–869
  67. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–323
  68. Ruhlmann J, Schomburg A, Bender H, et al.  Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum. 1997;40:1195–1204
  69. Valk PE, Abella-Columna E, Haseman MK, et al.  Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503–511
  70. Moertel CG, Fleming TR, Macdonald JS, et al.  An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA. 1993;270:943–947
  71. Vitola JV, Delbeke D, Sandler MP, et al.  Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171:21–26
  72. Romer W, Hanauske AR, Ziegler S, et al.  Positron emission tomography in non-Hodgkin’s lymphoma (assessment of chemotherapy with fluorodeoxyglucose). Blood. 1998;91:4464–4471
  73. Kostakoglu L, Coleman M, Leonard JP, et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–1027
  74. Stumpe KD, Urbinelli M, Steinert HC, et al.  Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma (Effectiveness and comparison with computed tomography). Eur J Nucl Med. 1998;25:721–728
  75. Weber WA, Ott K, Becker K, et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–3065
  76. Findlay M, Young H, Cunningham D, et al.  Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases (Correlation with tumor response to fluorouracil). J Clin Oncol. 1996;14:700–708
  77. Demetri GD, von Mehren M, Blanke CD, et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  78. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47–59
  79. Zhuang H, Duarte PS, Pourdehnad M, et al.  The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med. 2001;42:44–48
  80. Manthey N, Reinhard P, Moog F, et al.  The use of [18 F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl Med Commun. 2002;23:645–653
  81. Vanquickenborne B, Maes A, Nuyts J, et al.  The value of (18)FDG-PET for the detection of infected hip prosthesis. Eur J Nucl Med Mol Imaging. 2003;30:705–715
  82. Zhuang H, Duart PS, Pourdehand M, et al.  Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med. 2000;25:281–284
  83. Guhlmann A, Brecht-Krauss D, Suger G, et al.  Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med. 1998;39:2145–2152
  84. Blockmans D, Knockaert D, Maes A, et al.  Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis. 2001;32:191–196
  85. Meller J, Altenvoerde G, Munzel U, et al.  Fever of unknown origin (prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET). Eur J Nucl Med. 2000;27:1617–1625
  86. Lorenzen J, Buchert R, Bohuslavizki KH. Value of FDG PET in patients with fever of unknown origin. Nucl Med Commun. 2001;22:779–783
  87. Neurath MF, Vehling D, Schunk K, et al.  Noninvasive assessment of Crohn’s disease activity (A comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies). Am J Gastroenterol. 2002;97:1978–1985
  88. Alavi A, Buchpiguel CA, Loessner A. Is there a role for FDG PET imaging in the management of patients with sarcoidosis?. J Nucl Med. 1994;35:1650–1652
  89. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994;35:1647–1649
  90. Ludwig V, Fordice S, Lamar R, et al.  Unsuspected skeletal sarcoidosis mimicking metastatic disease on FDG positron emission tomography and bone scintigraphy. Clin Nucl Med. 2003;28:176–179
  91. Yasuda S, Shohtsu A, Ide M, et al.  High fluorine-18 labeled deoxyglucose uptake in sarcoidosis. Clin Nucl Med. 1996;21:983–984
  92. Polisson RP, Schoenberg OI, Fischman A, et al.  Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:819–825
  93. Hara M, Goodman PC, Leder RA. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr. 1999;23:16–18
  94. Derdelinckx I, Maes A, Bogaert J, et al.  Positron emission tomography scan in the diagnosis and follow-up of aortitis of the thoracic aorta. Acta Cardiol. 2000;55:193–195
  95. Blockmans D, Maes A, Stroobants S, et al.  New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford). 1999;38:444–447
  96. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med. 1996;37:1701–1712
  97. deKemp RA, Ruddy TD, Hewitt T, et al.  Detection of serial changes in absolute myocardial perfusion with 82Rb PET. J Nucl Med. 2000;41:1426–1435
  98. Yun M, Jang S, Cucchiara A, et al.  18F FDG uptake in the large arteries (A correlation study with the atherogenic risk factors). Semin Nucl Med. 2002;32:70–76
  99. Vallabhajosula S, Machac J, Knesaurek K, et al.  Imaging atherosclerotic macrophage density by positron emission tomography using F-18-fluorodeoxyglucose. J Nucl Med. 1996;37:38; (abstr)
  100. Blake GM, Park-Holohan SJ, Cook GJ, et al.  Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31:28–49
  101. van Eijkeren ME, Thierens H, Seuntjens J, et al.  Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck. Acta Oncol. 1996;35:737–741
  102. Vander Borght T, Labar D, Pauwels S, et al.  Production of [2–11C]thymidine for quantification of cellular proliferation with PET. Int J Rad Appl Instrum [A]. 1991;42:103–104
  103. Barthel H, Cleij MC, Collingridge DR, et al.  3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791–3798
  104. Buck AK, Schirrmeister H, Hetzel M, et al.  3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62:3331–3334
  105. Wagner M, Seitz U, Buck A, et al.  3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681–2687
  106. Shields AF, Grierson JR, Dohmen BM, et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  107. Koh WJ, Bergman KS, Rasey JS, et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391–398
  108. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265–280
  109. Fujibayashi Y, Taniuchi H, Yonekura Y, et al.  Copper-62-ATSM (a new hypoxia imaging agent with high membrane permeability and low redox potential). J Nucl Med. 1997;38:1155–1160
  110. Evans SM, Kachur AV, Shiue CY, et al.  Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med. 2000;41:327–336
  111. Dolbier WR, Li AR, Koch CJ, et al.  [18F]-EF5, a marker for PET detection of hypoxia (Synthesis of precursor and a new fluorination procedure). Appl Radiat Isot. 2001;54:73–80
  112. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging. 2002;16:352–361
  113. Eliceiri BP, Cheresh DA. The role of alpha-v integrins during angiogenesis (insights into potential mechanisms of action and clinical development). J Clin Invest. 1999;103:1227–1230
  114. Cheresh DA. Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. Cancer Metastasis Rev. 1991;10:3–10
  115. Haubner R, Wester HJ, Weber WA, et al.  Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–1785
  116. Haubner R, Wester HJ, Burkhart F, et al.  Glycosylated RGD-containing peptides (Tracer for tumor targeting and angiogenesis imaging with improved biokinetics). J Nucl Med. 2001;42:326–336
  117. Kaminski MS, Zelenetz AD, Press OW, et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–3928
  118. Witzig TE, Gordon LI, Cabanillas F, et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463
  119. Anderson CJ, Connett JM, Schwarz SW, et al.  Copper-64-labeled antibodies for PET imaging. J Nucl Med. 1992;33:1685–1691
  120. Henze M, Schuhmacher J, Hipp P, et al.  PET imaging of somatostatin receptors using. J Nucl Med. 2001;42:1053–1056
  121. Ogawa T, Shishido F, Kanno I, et al.  Cerebral glioma (Evaluation with methionine PET). Radiology. 1993;186:45–53
  122. Jager PL, Vaalburg W, Pruim J, et al.  Radiolabeled amino acids (Basic aspects and clinical applications in oncology). J Nucl Med. 2001;42:432–445
  123. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990–995
  124. Kotzerke J, Prang J, Neumaier B, et al.  Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415–1419
  125. Price DT, Coleman RE, Liao RP, et al.  Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168:273–280
  126. Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med. 2003;44:556–558
  127. Oyama N, Akino H, Kanamura H, et al.  11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–186
  128. Mortimer JE, Dehdashti F, Siegel BA, et al.  Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer (Correlation with estrogen receptor status and response to systemic therapy). Clin Cancer Res. 1996;2:933–939
  129. Dehdashti F, Mortimer JE, Siegel BA, et al.  Positron tomographic assessment of estrogen receptors in breast cancer (Comparison with FDG-PET and in vitro receptor assays). J Nucl Med. 1995;36:1766–1774
  130. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683–693
  131. Lin EC, Quaife RA. FDG uptake in chronic superior vena cava thrombus on positron emission tomographic imaging. Clin Nucl Med. 2001;26:241–242
  132. Chang KJ, Zhuang H, Alavi A. Detection of chronic recurrent lower extremity deep venous thrombosis on fluorine-18 fluorodeoxyglucose positron emission tomography. Clin Nucl Med. 2000;25:838–839
  133. Zhuang H, Pourdehnad M, Lambright ES, et al.  Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–1417
  134. Matthies A, Hickeson M, Cuchiara A, et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–875
  135. Suzuki S, Toyota T, Suzuki H, et al.  Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase. Arch Biochem Biophys. 1984;235:418–426
  136. Nelson CA, Wang JQ, Leav I, et al.  The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol. 1996;23:533–541
  137. Gallagher BM, Fowler JS, Gutterson NI, et al.  Metabolic trapping as a principle of radiopharmaceutical design (Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose). J Nucl Med. 1978;19:1154–1161
  138. Townsend DW, Cherry SR. Combining anatomy and function (The path to true image fusion). Eur Radiol. 2001;11:1968–1974
  139. Townsend DW. A combined PET/CT scanner (The choices). J Nucl Med. 2001;42:533–534
  140. Cohade C, Osman M, Marshall LN, et al.  PET-CT (Accuracy of PET and CT spatial registration of lung lesions). Eur J Nucl Med Mol Imaging. 2003;30:721–726
  141. Costa DC, Visvikis D, Crosdale I, et al.  Positron emission and computed X-ray tomography (A coming together). Nucl Med Commun. 2003;24:351–358
  142. Lardinois D, Weder W, Hany TF, et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–2507

PII: S0001-2998(03)00073-4

doi: 10.1053/j.semnuclmed.2003.09.007

Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 56-69 , January 2004

Article Tools